Dr. Diyuan Li

Postdoctoral Researcher

Diyuan Li obtained his BSc degree in pharmacy at China Pharmaceutical University (2014) and MSc in Chemistry from The University of Manchester (2016). He has two industrial experiences: synthesis of Tofacitinib, a new drug of Pfizer at Jinlixin Medical Co.Ltd. (2014) and drug intermediate synthesis and scale up at Peptech corp., China (2017). He holds a PhD degree in organic chemistry from University College London (Dr Wilden’s group), where he acquired a great deal of experience with radical chemistry and electrosynthesis. From July 2021 to May 2022, he was a postdoctoral research fellow at University of Nottingham, where he focused on visible light induced peptide and protein modification.